v3.26.1
Segment reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment reporting [Text Block]

10. Segment reporting

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company manages the business activities on a consolidated basis and operates as one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company’s product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company’s CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. The significant segment expense categories (general and administrative and research and development) are consistent with those presented on the face of the statements of operations and comprehensive loss. Other segment items are interest (income) expenses which are consistent with those presented on the face of the statements of operations and comprehensive loss. Additionally, the CODM reviews cash forecast models to determine where the Company will invest in planned research and development activities. As the Company’s operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as Total Assets. Segment asset information is not used by the CODM to allocate resources.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to consolidated operating expenses as the Company’s single segment operating loss for the three and six months ended June 30, 2026 and 2025 is included in the table below:

    Three Months Ended June 30,     Six Months Ended June 30,  
    2026     2025     2026     2025  
Research and development expenses:                        
SkinJect                        
Clinical, manufacturing and regulatory activities   1,268,747     1,011,362     2,011,288     2,453,931  
Professional services and intellectual property   96,653     71,561     145,227     116,678  
Teverelix                        
Clinical, manufacturing and regulatory activities   2,927,793     -     3,850,023     -  
Professional services and intellectual property   46,169     -     78,341     -  
Salaries and benefits   568,329     356,641     1,527,207     875,169  
Total research and development expenses   4,907,692     1,439,564     7,612,085     3,445,778  
Total general and administrative expenses   6,571,097     4,576,524     12,463,781     7,696,584  
Total operating expenses   11,478,789     6,016,088     20,075,866     11,142,362  
Other income (expense):                        
Finance income   -     40,004     -     63,870  
Interest income (expense)   (205,638 )   -     (523,789 )   -  
Loss on SEPA settlements   -     -     (127,083 )   -  
Change in fair value of debentures   -     (200,000 )         (200,000 )
Total other income (expense)   (205,638 )   (159,996 )   (650,872 )   (136,130 )
Net loss for the period   (11,684,427 )   (6,176,084 )   (20,726,738 )   (11,278,492 )